XGN Long Call Strategy

XGN (Exagen Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NASDAQ.

Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications.

XGN (Exagen Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $110.7M, a beta of 2.02 versus the broader market, a 52-week range of 2.59-12.23, average daily share volume of 383K, a public-listing history dating back to 2019, approximately 209 full-time employees. These structural characteristics shape how XGN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.02 indicates XGN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on XGN?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current XGN snapshot

As of June 29, 2026, spot at $4.79, ATM IV 212.90%, IV rank 41.40%, expected move 61.04%. The long call on XGN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.

Why this long call structure on XGN specifically: XGN IV at 212.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 61.04% (roughly $2.92 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated XGN expiries trade a higher absolute premium for lower per-day decay. Position sizing on XGN should anchor to the underlying notional of $4.79 per share and to the trader's directional view on XGN stock.

XGN long call setup

The XGN long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With XGN near $4.79, the first option leg uses a $4.79 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed XGN chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 XGN shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$4.79N/A

XGN long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

XGN long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on XGN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on XGN

Long calls on XGN express a bullish thesis with defined risk; traders use them ahead of XGN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

XGN thesis for this long call

The market-implied 1-standard-deviation range for XGN extends from approximately $1.87 on the downside to $7.71 on the upside. A XGN long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current XGN IV rank near 41.40% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on XGN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, XGN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to XGN-specific events.

XGN long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. XGN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move XGN alongside the broader basket even when XGN-specific fundamentals are unchanged. Long-premium structures like a long call on XGN are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current XGN chain quotes before placing a trade.

Frequently asked questions

What is a long call on XGN?
A long call on XGN is the long call strategy applied to XGN (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With XGN stock trading near $4.79, the strikes shown on this page are snapped to the nearest listed XGN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are XGN long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the XGN long call priced from the end-of-day chain at a 30-day expiry (ATM IV 212.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a XGN long call?
The breakeven for the XGN long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XGN market-implied 1-standard-deviation expected move is approximately 61.04%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on XGN?
Long calls on XGN express a bullish thesis with defined risk; traders use them ahead of XGN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current XGN implied volatility affect this long call?
XGN ATM IV is at 212.90% with IV rank near 41.40%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related XGN analysis